Skip to content

ED50 of Ciprofol Combined with Alfentanil for Suppression of Laryngeal Mask Airway Insertion Responses in Patients Undergoing Gynecological Laparoscopic Surgery

ED50 of Ciprofol Combined with Alfentanil for Suppression of Laryngeal Mask Airway Insertion Responses in Patients Undergoing Gynecological Laparoscopic Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114754
Enrollment
Unknown
Registered
2025-12-17
Start date
2025-12-22
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological diseases

Interventions

Ciprofol group:Ciprofol administered intravenously at an initial dose of 0.36 mg/kg, adjusted sequentially using the up-and-down method with a step of 0.04 mg/kg, combined with a fixed dose of alfenta
Propofol:Patients receive intravenous propofol at an initial dose of 1.5 mg/kg, with a dose adjustment step of 0.5 mg/kg, combined with a fixed dose of alfentanil 15 µg/kg. Laryngeal mask airway inser

Sponsors

Tai'an Central Hospital (Qingdao University Affiliated Tai'an Central Hospital, Taishan Medical Care Center)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Female patients aged 18–65 years; 2.American Society of Anesthesiologists (ASA) physical status I–II; 3.Patients scheduled for elective gynecological laparoscopic surgery under general anesthesia, with planned laryngeal mask airway ventilation; 4.Body mass index (BMI) between 18.5 and 30 kg/m^2; 5.Airway assessment of Mallampati class I–II, with no anticipated difficult airway; 6.Patients who provide informed consent and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Individuals with known allergies to ciprofol , alfentanil, propofol, or any components of their formulations; 2.Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, or serious endocrine or metabolic disorders; 3.Patients with severe anemia (Hb 35 kg/m^2); 6.Patients on long-term use of sedative-hypnotics, opioid analgesics, or psychotropic medications; 7.Other conditions deemed by the investigators as unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Laryngeal mask airway insertion response;

Secondary

MeasureTime frame
Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), peripheral oxygen saturation (SpO?), and bispectral index (BIS).;

Countries

China

Contacts

Public ContactTianran Zhang

Tai'an Central Hospital (Qingdao University Affiliated Tai'an Central Hospital, Taishan Medical Care Center)

934052853@qq.com+86 155 0538 7971

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026